Costa Simonetta, Zecca Enrico, De Luca Daniele, De Carolis Maria Pia, Romagnoli Costantino
Division of Neonatology, Department of Paediatrics, Catholic University of the Sacred Heart, Rome, Italy.
Eur J Obstet Gynecol Reprod Biol. 2007 Apr;131(2):154-7. doi: 10.1016/j.ejogrb.2006.05.006. Epub 2006 Jun 23.
To assess the effectiveness of an incomplete course of antenatal corticosteroids (ACS) on neonatal morbidity and mortality of preterm infants.
Preterm infants born at 25-34 weeks' gestational age between January 1, 1998 and December 31, 2003 were included in this study. Studied infants were divided in two groups: the ACS group included those infants who had been exposed to a single 12-mg dose of betamethasone before delivery while the control group included those infants who had been delivered without any antenatal corticosteroids treatment. The most important neonatal outcomes were compared between the two groups.
One hundred and seventy neonates (41.4%) were exposed to one 12-mg dose of betamethasone before delivery, while 241 neonates (58.6%) did not receive any antenatal corticosteroids treatment. Mean gestational age at delivery (30.4+/-2.4 weeks versus 31.2+/-2.9 weeks, p=0.004) and mean birth weight (1375+/-454 g versus 1625+/-580 g, p<0.001) were lower in the ACS group. The univariate analysis showed that delivery room intubation and respiratory distress syndrome were more frequent in the ACS group and that the length of stay was also significantly longer in this group. No differences were found concerning survival, neonatal morbidity, need for and duration of mechanical ventilation and oxygen therapy. The incidence of major outcomes in survivors was also similar. Logistic regression adjusted for gestational age showed that the exposure to a single dose of betamethasone before delivery was not associated with a significant reduction in the rate of any neonatal outcome. We also compared the outcomes in function of gestational age subclasses. In the 25-27 weeks subgroup, delivery room intubation, surfactant treatment and patent ductus arteriosus (PDA) were less frequent in ACS infants; they had also shorter ventilation and oxygen duration. In the 30-31 weeks subgroup, ACS infants had a lower incidence of mechanical ventilation and a shorter duration of oxygen therapy. Finally, no differences were found in the 28-29 weeks subgroup and in the 32-34 weeks subgroup.
Effects of incomplete antenatal corticosteroids are variable: they give some benefits to infants of 25-27 weeks gestational age, fail to show any difference in outcomes in the 32-34 weeks subgroup and are doubtful between these extremes.
评估产前皮质类固醇激素(ACS)疗程不完整对早产儿新生儿发病率和死亡率的影响。
本研究纳入了1998年1月1日至2003年12月31日期间出生的孕25 - 34周的早产儿。研究对象分为两组:ACS组包括那些在分娩前接受过单次12毫克倍他米松治疗的婴儿,而对照组包括那些未接受任何产前皮质类固醇激素治疗的婴儿。比较两组最重要的新生儿结局。
170例新生儿(41.4%)在分娩前接受了单次12毫克倍他米松治疗,而241例新生儿(58.6%)未接受任何产前皮质类固醇激素治疗。ACS组的平均分娩孕周(30.4±2.4周对31.2±2.9周,p = 0.004)和平均出生体重(1375±454克对1625±580克,p<0.001)较低。单因素分析显示,ACS组产房插管和呼吸窘迫综合征更为常见,且该组住院时间也明显更长。在生存、新生儿发病率、机械通气需求及持续时间和氧疗方面未发现差异。存活者的主要结局发生率也相似。经孕周调整的逻辑回归显示,分娩前单次暴露于倍他米松与任何新生儿结局发生率的显著降低无关。我们还比较了不同孕周亚组的结局。在25 - 27周亚组中,ACS组婴儿的产房插管、表面活性剂治疗和动脉导管未闭(PDA)发生率较低;他们的通气和吸氧持续时间也较短。在30 - 31周亚组中,ACS组婴儿机械通气发生率较低且氧疗持续时间较短。最后,在28 - 29周亚组和32 - 34周亚组中未发现差异。
产前皮质类固醇激素疗程不完整的影响是可变的:它们对孕25 - 27周的婴儿有一些益处,在32 - 34周亚组的结局中未显示出任何差异,在这两个极端之间的情况则不确定。